Lannett Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for LANNETT, and what generic and branded alternatives to LANNETT drugs are available?
LANNETT has one hundred and forty-four approved drugs.
There is one tentative approval on LANNETT drugs.
Summary for Lannett
US Patents: | 0 |
Tradenames: | 106 |
Ingredients: | 101 |
NDAs: | 144 |
Patent Litigation for Lannett: | See patent lawsuits for Lannett |
PTAB Cases with Lannett as petitioner: | See PTAB cases with Lannett as petitioner |
Drugs and US Patents for Lannett
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lannett Co Inc | CHLORPROMAZINE HYDROCHLORIDE | chlorpromazine hydrochloride | TABLET;ORAL | 212996-004 | Jan 22, 2021 | AB | RX | No | No | See Plans and Pricing | See Plans and Pricing | ||||
Lannett | BETHANECHOL CHLORIDE | bethanechol chloride | TABLET;ORAL | 084702-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | See Plans and Pricing | See Plans and Pricing | |||||
Lannett Co Inc | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 205022-001 | Sep 19, 2016 | AB | RX | No | No | See Plans and Pricing | See Plans and Pricing | ||||
Lannett Co Inc | TERBUTALINE SULFATE | terbutaline sulfate | TABLET;ORAL | 077152-001 | Mar 25, 2005 | AB | RX | No | No | See Plans and Pricing | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Lannett
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Lannett Co Inc | MYKROX | metolazone | TABLET;ORAL | 019532-001 | Oct 30, 1987 | 4,517,179 | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for LANNETT drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
Similar Applicant Names
Here is a list of applicants with similar names.